Late breaking abstract L19 Study on the efficacy & safety of Emapalumab in treating Macrophage Activation Syndrome (MAS) in Still's Disease. Key findings: - 53.8% achieved complete response (CR) at Week 8; 85% at any time. - Rapid reduction in hyperinflammation biomarkers… https://t.co/VcmUdRP6PV https://t.co/r7AMt0IjYk